An Open Trial to Asses the Tolerability of AVANZ Mite Mix Immunotherapy

Trial Profile

An Open Trial to Asses the Tolerability of AVANZ Mite Mix Immunotherapy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jan 2015

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors ALK-Abello
  • Most Recent Events

    • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Mar 2012 Additional lead trial investigator (Tabar AI) identified as reported by ClinicalTrials.gov.
    • 30 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01568190).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top